- A death row inmate wants to donate a kidney. Texas won’t let him.
- How well does Paxlovid really work?
- Casey Mulligan and Joe Grogan defend PBMs. (WSJ)
- More on surprise bills: they occur in one in five emergency room visits and up to one in six in-network hospital stays.
- The Baduy, an indigenous group in Indonesia, have rejected vaccinations. Their Covid death toll: zero. (NYT)
- More on circadian rhythms: mice live longer if they eat on the right time schedule. (DMN)
Category: Policy & Legislation
Wednesday Links
- How an economist thinks about abortion. Well, at least one economist.
- Why is Google investing in health care?
- Is developing Covid vaccines a profitable venture for drug companies? “The answer is a resounding ‘no’. In fact, in most cases, developing mRNA vaccines for a portfolio of emerging diseases would be a money loser.”
- How common is prior authorization?
- Price controls on insulin: The (intended?) result will that be that consumers will pay more, diabetes complications will get worse, and incumbent manufacturers will make more money.
- Almost a quarter of Americans over the age of 18 are now medicated for one or more of these conditions. (HT: Tyler)
- Canada’s health care providers say their system is “collapsing.”
Will the Covid Emergency Ever End?
PHOTO: GETTY IMAGES/ISTOCKPHOTO It’s supposed to end on Friday. But the Wall Street Journal says that continued extensions are the left’s best way of expanding the welfare state. One reason is that in March 2020 Congress barred states from kicking ineligible people off Medicaid rolls during the emergency in return for more federal funding. Medicaid enrollment has ballooned to…
Drug Maker Applies to Sell The Pill Over the Counter without a Prescription
According to the New York Times the US Food and Drug Administration has received an application by a drug company to switch a prescription birth control pill to over-the-counter status. A Paris-based company, HRA Pharma asked the FDA to make its pill legal to sell without a prescription. That move is controversial, not just because of the recent Supreme Court ruling on Roe v Wade. Another pill manufacturer, Cadence Health, is also preparing to submit an application to switch its pill to OTC as well.